Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 978531, 6 pages
Review Article

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

Division of Medical Oncology, University of Colorado Denver School of Medicine, 12801 E. 17th Avenue, Room L18-8117, Aurora, CO 80045, USA

Received 4 August 2011; Accepted 20 December 2011

Academic Editor: Hirotsugu Uemura

Copyright © 2012 Xiaoyu Hou and Thomas W. Flaig. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer is the most common cancer among men in the United States. For decades, the cornerstone of medical treatment for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation Therapy (ADT). The development of hormone-resistant prostate cancer (now termed castration-resistant prostate cancer:CRPC) remains the key roadblock in successful long-term management of prostate cancer. New advancements in medical therapy for prostate cancer have added to the hormonal therapy armamentarium. These new therapeutic agents not only provide a survival benefit but also show potential for reversing hormonal resistance in metastatic CRPC, and thus redefining hormonally sensitive disease.